Related Experiment Videos
High-throughput fluorescence flow-injection topoisomerase II inhibition assay
1Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada.
Journal of Chromatography. B, Biomedical Sciences and Applications
|September 4, 2001
Summary
A new fluorescence flow-injection assay enables rapid screening of DNA topoisomerase II inhibitors for cancer drug development. This method offers a faster, more sensitive alternative to existing assays for identifying potential anticancer agents.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- DNA topoisomerase II is a crucial target for anticancer drugs.
- Existing methods for assessing topoisomerase II inhibition are often slow and labor-intensive.
Purpose of the Study:
- To develop a high-throughput fluorescence assay for evaluating DNA topoisomerase II catalytic inhibition.
- To provide a rapid and accurate method for screening potential anticancer topoisomerase II inhibitors.
Main Methods:
- A fluorescence flow-injection assay was established.
- High molecular mass trypanosome kinetoplast DNA was separated from its decatenated product via centrifugation.
- The assay measures the inhibition of DNA decatenation.
Main Results:
- The developed assay is faster and more sensitive than traditional agarose gel electrophoresis and radioactive centrifugation assays.
- The assay demonstrates a highly linear response to product formation.
- It eliminates the need for radioactive DNA substrates.
Conclusions:
- The fluorescence flow-injection assay is a valuable tool for high-throughput screening of topoisomerase II inhibitors.
- This method facilitates the rapid and accurate determination of inhibition constants for potential anticancer drugs.